Safety Study of Rufinamide Given as an add-on Therapy to Treat Patients With Seizures
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study will evaluate the efficacy and safety of Rufinamide in reducing seizure frequency in subjects with partial seizures not fully controlled despite treatment with 1 to 3 concomitant antiepileptic drugs.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
12 Years to 80 Years (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male and Female patients between 12 and 80 years of age
Dx of epilepsy with partial onset seizures woth or woth out secondarily generalized seizures
Non controlled partial seizures despite treatment with 2 different AEDs for at least 2 years
must have 6 seizures during baseline
current treatment with maximum of 3 AEDs
stable dose of AED(s)for at least 1 month
if patient has VNS, must have been implanted 6 months prior to randomization
Participation in any investigational product for at least 1 month prior to visit 1
Presence of non-motor simple partial seizures only
presence of generalized epilepsies
Evidence of clinically significant disease
Clinically significant ECG
Psychogenic seizure in previous year
History of drug/alcohol abuse
History of suicide attempt
Multiple drug allergies
Concomitant felbamate use
Need for frequent rescue benzodiazepines
Concomitant use of vigabatrin
All patients diagnosed with congenital short QT syndrome